AFT Pharmaceuticals Expands US Maxigesic Partnership with Hikma

AFT Pharmaceuticals Ltd. ( (AU:AFP) ) has provided an update.

AFT Pharmaceuticals has extended its US licensing agreement with Hikma Pharmaceuticals for its Maxigesic pain relief products. The agreement allows Hikma to manage all channels for Combogesic Rapid in the US, enhancing the marketing of both intravenous and tablet forms across the entire US market. This strategic move aims to improve commercial benefits and patient care by offering non-opioid pain relief options, potentially reducing risks associated with opioid use in postoperative care. The restructuring of profit-sharing arrangements and increased involvement in sales and marketing planning are expected to bolster AFT’s position in the US pain relief market.

More about AFT Pharmaceuticals Ltd.

AFT Pharmaceuticals is a New Zealand-based multinational pharmaceutical company that develops, markets, and distributes a diverse portfolio of pharmaceutical products across various therapeutic categories. The company operates in major pharmaceutical distribution channels, including over-the-counter, prescription, and hospital sectors. AFT’s business model involves developing and in-licensing products for markets in regions such as Australia, New Zealand, the USA, and the EU, while out-licensing to local distributors in over 125 countries.

Average Trading Volume: 3,165

Technical Sentiment Signal: Sell

Current Market Cap: A$268.6M

Find detailed analytics on AFP stock on TipRanks’ Stock Analysis page.